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A b s t r a c t  
To report the virtual screening of several series of Indolo Pyrimidine derivatives for in silico 
KSP inhibition to arrive at possible potential inhibitors of KSP with acceptable pharmacokinetic 
or ADMET properties. 
In order to identify potential inhibitors we employed various computational approaches. In this 
work, we computationally screened and analyzed 60 analogs and further tested their ADME/T 
profiles. Library of the molecules was constructed based upon structural modifications of 
pyrimidines and indole nucleus. Structural modifications were performed for the series of 4-(3-
hydroxyphenyl)-6-methyl-2-oxo-N-substituted[(Z)-(2-oxoindolin-3-ylidene)amino]-3,4-dihydro-
1H-pyrimidine-5-carboxamide derivatives in an order to get better  binding energies as 
compared with Ispinseb. The molecules with better (lower) binding energies were subjected to 
predict ADMET properties.  
Ten molecules from the series IP1-IP60 were found acceptable with binding energies and 
pharmacokinetic properties. On the basis of the binding energies and ADMET properties we 
have identified compound IP2 and IP4 to be the best interacting molecules. The molecules with 
acceptable ADMET properties and better binding energies were prioritized for synthesis and 
anticancer evaluation.  
The binding energies and ADMET of the drugs provided suggests the protein ligand binding 
interactions that can aid in the design and synthesis of more potential inhibitors. 
Keywords: KSP inhibitors, virtual screening, ADMET and Indolo Pyrimidines. 
 
Introduction 
Kinesin spindle protein (KSP), also known as Hs Eg5 has emerged 
as a promising target for a new generation antimitotic 
chemotherapeutic agents, it is a member of the kinesin superfamily 
of molecular motors that utilize the energy generated from the 
hydrolysis of ATP to transport vesicles, organelles, and 
microtubules [1-3]. 
 Ispinesib has emerged as a potent KSP inhibitor with sub 
nanomolar Ki having a quinazolinone core is an experimental KSP 
inhibitor from Cytokinetics which has already entered clinical 
trials.The “Biginelli reaction” that leads to dihydropyrimidines is one 
of the most famous Multi Component Reactions (MCRs). It was first 
reported by the Bignelli in 1893 who obtained the important 
multifunctionalized heterocycle by refluxing a mixture of an 
aldehyde, a b-ketoester, and urea in the presence of an acid 
catalyst. This reaction was named as Biginelli reaction and the 
product as Biginelli product.  
 
Inhibition of KSP prevents normal bipolar spindle formation, which 
leads to mitotic arrest with a characteristic monastrol phenotype 
and subsequently to apoptosis in transformed cells. KSP inhibition 
represents a novel and specific mechanism to target the mitotic 
spindle that may be devoid of the neuropathy associated, 
mechanism based side effects common to the taxanes and other 
natural products that target the microtubules [4-6].  
The discovery of monastrol, a small, specific, and cell permeable 
KSP inhibitor, led to several other small molecules as KSP 
inhibitors. It was reported by Mayer in 1999, considered to be the 
first small molecule. It targets KSP and led to mitotic arrest. The 
crystal structure KSP complex with Mg2+ and ADP has been 
determined by Turner et al. the binding mode of the monastrol was 
then reported in detail by Yan et al. after discovering monastrol 
several classes of compounds have been reported. This makes it to 
possible to make a binding mode analysis for KSP inhibitors. In the 
present report we have designed Biginelli compound analogous to 
Monastrol with different isatins.  Only 10 compounds out of 100, 
which were designed and studied for 2D QSAR and ADMET were 
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Designing of the molecules and library design 
 
A library of the molecules was generated by performing structural 
modifications in descending order on the series of Indolo-
Pyrimidine molecules. Structural modifications were carried out on 
pyrimidines and Indoles and molecules were generated in 3D. This 
generated set of 60 ligands from series 4-(3-hydroxyphenyl)-6-
methyl-2-oxo-N-[(Z)-(2-oxo-substituted indolin-3-ylidene)amino]-






Discovery studio visualization program accelrys [11] is utilized to 
visualize the receptors, ligand structures, hydrogen bonding 
network, to calculate length of the bonds and to render images. 
Biovia Draw is used to draw the ligand compounds. Auto dock 4.0.1 
[12] is the primary docking program used in this work for the semi-
flexible docking studies. Data warrior property explorer program 
was used to study the ADMET and 2D QSAR properties of the 
compounds. 
 
Docking by Virtual Screening 
 
PyRx is used to predict binding pose with associated energy 
prediction of the compounds with drug target KSP domain. Protocol 
followed for carrying out the docking studies using PyRx virtual tool 
in order to predict binding pose along with associated binding 
energies is of default parameters similar to the protocol followed 
elsewhere. Briefly, the energy scoring grid box was set to 126, 126 
and 126 Å (x, y, and z) centered at X = 34.4092; Y = 26.4643 and Z 
= 11.1914 with 0.375 angstroms grid points spacing assigned with 
default atomic salvation parameters. The grid box was designed 
such that the active site of KSP domain was surrounded by the 
three dimensional grid box centered at its active ligand binding site 
location. Lamarckian Genetic Algorithm (LGA) [13] was selected as 
docking engine, with all the docking parameters set to default. After 
each LGA run, Auto dock reports the best docking solution for each 
docked complex, and the results are reported based on cluster 
analysis. Binding Gibbs free energy (ΔG) is calculated as a sum of 
six energy terms of dispersion/repulsion, electrostatic interactions, 
hydrogen bonding, deviation from covalent geometry, desolvation 
effects and internal ligand torsional constraints. From a total of 10 
docking modes represented by LGA cluster analysis, the lowest 
energy docking mode was selected from each docking simulation.  
 
Pharmacological properties of the compounds  
 
Data warrior software [14] was used to check the pharmaceutical 
fidelity of the drug candidates. Molecular descriptors, such as Log 
P, the number of hydrogen bond donors, the number of hydrogen 
bond acceptors, and the molecular mass and toxicity of the 
compounds were analyzed.  
 
Results and Discussion  
 
Docking of the compounds with KSP domain active site  
 
We have performed the docking studies for the present studied 60 
compounds with the KSP domain protein targeting its active binding 
site in order to know the binding energy involved in this complex 
formation. Docking results are tabulated in Table 1. In this present 
work only ten compounds have shown to be successfully docking 
inside the active site of KSP domain with a binding energy in a 
range of -7.7 to -7.0 Kcal/mol. We have compared our docking 
results with Ispinesib (N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-
chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide) 
under clnical trial for KSP, showing binding energy of -5.2 Kcal/mol. 
It was identified that all the compounds are showing better binding 
energies than these control by showing -7.7 to -7.0 Kcal/mol of 
binding energy respectively. As per the molecular docking results, it 
was revealed that compounds IP2 and IP4 have the best estimated 
-7.7 Kcal/mol of binding energy Table 1 for the KSP domain 
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Prediction of pharmacological properties 
  
Data warrior was utilized to predict the pharmacological properties 
of the present studied compounds according to Lipinski’s Rule of 
Five [15]. The pharmacological attributes prediction results are 
displayed in Table 2.  
Based on the experimental values, it was inferred that all the ten 
compounds successfully satisfied all the parameters of Lipinski’s 
Rule of Five. The parameters of the Lipinski’s rule are as follows: 
the molecular weight must be < 500 Da, Log P < 5, the number of 
hydrogen donors must be < 5, the number of acceptor hydrogen’s 
must be < 10, and the refractivity molar range must be between 
40–130. However, one parameter exception can be given out of 
above mentioned ones. As per the veber’s rule [16] oral 
bioavailability of drugs could be measured by the molecular weight, 
number of rotatable bonds (n rotb), number of hydrogen bonds, and 
the expanse of the drug’s polar surface (TPSA). The oral 
bioavailability was marked by small molecular weight (less than 500 
Da); also, the number of rotatable bond must be less than 10, the 
number of hydrogen bond donors and acceptors must be less than 
12, and TPSA values less than 140. Table 2 shows that all the 
compounds have a promising oral bioavaibility.  
 
Table 2: Docking results of the pyrimidine coumarin series of compounds with KSP domain 
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Screening for the best compound based on docking and 
drug likeliness results  
 
Keeping in view of binding energies of the present investigated 
compounds it was found that only ten compounds has the 
promising ADMET and 2D QSAR properties. Among ten 
compounds, compound IP2 i.e 4-(3-hydroxyphenyl)-6-methyl-N-
[(Z)-(5-methyl-2-oxo-indolin-3-ylidene)amino]-2-oxo-3,4-dihydro-
1H-pyrimidine-5-carboxamide, compound IP4 i.e (3Z)-3-[[4-(3-
hydroxyphenyl)-6-methyl-2-oxo-3,4-dihydro-1H-pyrimidine-5-
carbonyl]hydrazono]-2-oxo-indoline-7-carboxylic acid  has the 
promising anti cancer drug like properties based on its ΔG binding 
energy. Based on Pharmacological properties, all the ten 
compounds showed good pharmacological attributes. These ten 
compounds were found to comply with Lipinski’s rule, Veber’s rule 
and oral bioavailability parameters. Whereas, compound IP2 and 
IP4 showed good pharmacological attributes, since it satisfied the 






Our In silico studies provides a rationalization to the ability of 
present studied novel ten compounds as a valuable small ligand 
molecule with strong binding affinity towards KSP domain for 
plausible anti-cancer activity involving large value of negative 
binding energy by forming various interactions with the residues. 
The knowledge gained through this present study could be of high 
value for computational screening of target specific KSP domain 
inhibitors by understanding the molecular interaction basis between 
ligand and receptor. On the other hand, promising ADMET and 2D 
QSAR drug like profile for the present compounds especially 
compound IP2 and IP4 substantiates the need of further evaluating 
this compounds ability to inhibit cancer. The present investigated 
indolo-pyrimidine scaffold of compounds offers the possibility of 
expedient additional modifications that could give rise to lead 
structures with enhanced inhibitory activity and selectivity towards 
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